Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Pacific Biosciences (PACB)
NASDAQ:PACB
Pacific Biosciences (PACB) Stock Price & Analysis
2,249 Followers
PACB Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$1.16 - $13.70
Previous Close$1.66
Volume5.24M
Average Volume (3M)9.99M
Market Cap
$452.11M
Enterprise Value$821.56M
Total Cash (Recent Filing)$561.91M
Total Debt (Recent Filing)$931.37M
Price to Earnings (P/E)―
Beta3.35
Next Earnings
Aug 07, 2024EPS Estimate
-$0.23Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.14
Shares Outstanding272,355,892
10 Day Avg. Volume6,539,806
30 Day Avg. Volume9,994,504
Standard Deviation0.25
R-Squared0.17
Alpha-0.02
Financial Highlights & Ratios
Price to Book (P/B)-1.52
Price to Sales (P/S)2.00
Price to Cash Flow (P/CF)-1.30
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue4.10
Enterprise Value/Gross Profit15.57
Enterprise Value/Ebitda-4.39
Forecast
1Y Price Target
$3.71Price Target Upside123.49% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering7
Pacific Biosciences News
PremiumCompany Announcements
Pacific Biosciences Shareholders Shape Company’s Strategic Future
Bulls Say, Bears Say
Bulls Say
Market ExpansionOnso shipments grew q/q in the quarter and the installed base now spans six continents.
Revenue GrowthPACB maintained FY24 revenue guidance of $170mn-$200mn.
Strategic InitiativesThe company is taking aggressive actions to reaccelerate growth while driving toward cash flow breakeven.
Bears Say
Customer BehaviorAn increasing number of customers delaying instrument purchases and softness in consumable shipments.
Market PerformanceSince being added to the Buy List on June 30, 2023, the stock is down 89% vs. S&P 500 up 14%.
Revenue Miss1Q revenue of $38.8mn missed Visible Alpha Consensus Data of $43.4mn.
---
Ownership Overview
3.98% Insiders
27.36% Mutual Funds
30.83% Other Institutional Investors
37.83% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
PACB FAQ
What was Pacific Biosciences’s price range in the past 12 months?
Pacific Biosciences lowest stock price was $1.16 and its highest was $13.70 in the past 12 months.
What is Pacific Biosciences’s market cap?
Currently, no data Available
When is Pacific Biosciences’s upcoming earnings report date?
Pacific Biosciences’s upcoming earnings report date is Aug 07, 2024 which is in 16 days.
How were Pacific Biosciences’s earnings last quarter?
Pacific Biosciences released its earnings results on May 09, 2024. The company reported -$0.29 earnings per share for the quarter, missing the consensus estimate of -$0.276 by -$0.014.
Is Pacific Biosciences overvalued?
According to Wall Street analysts Pacific Biosciences’s price is currently Undervalued.
Does Pacific Biosciences pay dividends?
Pacific Biosciences does not currently pay dividends.
What is Pacific Biosciences’s EPS estimate?
Pacific Biosciences’s EPS estimate is -$0.23.
How many shares outstanding does Pacific Biosciences have?
Pacific Biosciences has 272,355,900 shares outstanding.
What happened to Pacific Biosciences’s price movement after its last earnings report?
Pacific Biosciences reported an EPS of -$0.29 in its last earnings report, missing expectations of -$0.276. Following the earnings report the stock price went up 2.907%.
Which hedge fund is a major shareholder of Pacific Biosciences?
Among the largest hedge funds holding Pacific Biosciences’s share is ARK Investment Management LLC. It holds Pacific Biosciences’s shares valued at 125M.
---
Pacific Biosciences Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$3.71 (123.49% Upside)
$3.71 (123.49% Upside)
Blogger Sentiment
Bullish
PACB Sentiment 75%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Decreased
By 4.2M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $10.7K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Positive
Last 7 Days ▲ 1.0%
Last 30 Days ▲ 2.2%
Last 30 Days ▲ 2.2%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-87.85%
12-Months-Change
Fundamentals
Return on Equity
-44.28%
Trailing 12-Months
Asset Growth
-11.94%
Trailing 12-Months
Company Description
Pacific Biosciences
Pacific Biosciences of California, Inc. engages in the development, manufacture and sale of an integrated platform for genetic analysis. Its products and services include PacBio sequel system, consumables, analytical software, and single molecule real-time (SMRT) compatible products. It operates through the following geographical segments: North America, Europe, and Asia Pacific. The company was founded by Stephen Turner and Joseph Vincent Bonventre on July 14, 2000 and is headquartered in Menlo Park, CA.
---
PACB Earnings Call
Q1 2024
0:00 / 0:00
---
PACB Stock 12 Month Forecast
Average Price Target
$3.71
▲(123.49% Upside)
Technical Analysis
Best Analysts Covering PACB
1 Year
1 Year Success Rate
5/16 ratings generated profit
1 Year Average Return
+13.83%
reiterated a buy rating 2 months ago
Copying Kyle Mikson CFA's trades and holding each position for 1 Year would result in 31.25% of your transactions generating a profit, with an average return of +13.83% per trade.
---